Fifty-six patients with advanced HCC were randomized to two treatment groups : ( @ ) CF-HAIC group -LSB- n = @ , @-FU , @ mg/m ( @ ) on days @-@ , and cisplatin , @ mg/m ( @ ) on day @ -RSB- and ( @ ) ACF-HAIC group -LSB- n = @ , adriamycin , @ mg/m ( @ ) on day @ , @-FU , @ mg/m ( @ ) on days @-@ , and cisplatin , @ mg/m ( @ ) on day @ -RSB- every @ weeks via an implantable port system .